当前位置:首页 - 行情中心 - 仟源医药(300254) - 财务分析 - 利润表

仟源医药

(300254)

  

流通市值:23.57亿  总市值:25.80亿
流通股本:2.27亿   总股本:2.48亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入372,995,932.54181,736,278.48846,606,161.05608,815,610.55
  营业收入372,995,932.54181,736,278.48846,606,161.05608,815,610.55
二、营业总成本353,806,273.79173,536,336.36792,256,406.11563,187,725.7
  营业成本116,232,891.8155,412,915.77280,157,407.4200,975,472.43
  税金及附加4,802,773.92,337,838.8211,363,900.387,602,907.74
  销售费用129,873,094.869,071,111.47302,495,118.14220,249,038.85
  管理费用63,346,121.0127,967,449.67125,912,367.6786,429,230.97
  研发费用27,725,300.3712,891,525.2856,533,374.2336,311,001.29
  财务费用11,826,091.95,855,495.3515,794,238.2911,620,074.42
  其中:利息费用11,923,412.635,945,558.6516,976,345.7112,338,642.78
  其中:利息收入177,263.12115,875.221,316,030833,309.79
三、其他经营收益
  加:投资收益113,156.5627,498.34,544,279.823,861,750.62
  资产处置收益7,895,012.667,881,410.527,507,360.717,406,904.13
  资产减值损失(新)911,697.7643,124.34-7,318,590.89-1,946,560.62
  信用减值损失(新)510,134.82-80,477.88-5,818,941.95-2,496,772.31
  其他收益2,349,598.391,315,409.0311,730,203.729,250,279.31
四、营业利润30,969,258.9417,386,906.4364,994,066.3561,703,485.98
  加:营业外收入9,024,543.496,099,294.6922,206,003.5512,775,457.35
  减:营业外支出4,430,200.211,235,939.126,557,442.191,071,602.25
五、利润总额35,563,602.2222,250,26280,642,627.7173,407,341.08
  减:所得税费用19,230,101.33,054,506.515,883,079.456,248,808.45
六、净利润16,333,500.9219,195,755.4974,759,548.2667,158,532.63
(一)按经营持续性分类
  持续经营净利润16,333,500.9219,195,755.4974,759,548.2667,158,532.63
(二)按所有权归属分类
  归属于母公司股东的净利润380,868.6710,390,380.7842,190,119.1844,153,255.59
  少数股东损益15,952,632.258,805,374.7132,569,429.0823,005,277.04
  扣除非经常损益后的净利润-5,011,716.562,790,407.825,228,696.3227,270,785.8
七、每股收益
  (一)基本每股收益00.040.170.18
  (二)稀释每股收益00.040.170.18
九、综合收益总额16,333,500.9219,195,755.4974,759,548.2667,158,532.63
  归属于母公司股东的综合收益总额380,868.6710,390,380.7842,190,119.1844,153,255.59
  归属于少数股东的综合收益总额15,952,632.258,805,374.7132,569,429.0823,005,277.04
公告日期2025-08-262025-04-192025-04-152024-10-24
审计意见(境内)标准无保留意见
TOP↑